Imprimis offers Turing competitor

Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) said it launched a low-cost alternative to toxoplasmosis drug Daraprim pyrimethamine from Turing Pharmaceuticals AG (New York, N.Y.). Imprimis priced its compounded formulation of pyrimethamine and leucovorin at $99 per 100-count bottle.

In September, media reports said Turing increased the price of Daraprim from $13.50 per pill to $750. Turing is the sole supplier of the antiparasitic drug, which lost patent exclusivity decades ago but had no generic competitiors (see BioCentury, Sept. 28). ...